121 213

Cited 98 times in

Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)

DC FieldValueLanguage
dc.contributor.author정현철-
dc.date.accessioned2015-01-06T16:32:29Z-
dc.date.available2015-01-06T16:32:29Z-
dc.date.issued2014-
dc.identifier.issn0171-5216-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/98299-
dc.description.abstractPURPOSE: Cisplatin plus 5-fluorouracil has been globally accepted as a standard regimen for the treatment for advanced gastric cancer. However, cisplatin has several disadvantages, including renal toxicity and the need for admission. S-1 plus cisplatin has become a standard treatment for advanced gastric cancer in East Asia. This phase III study was designed to evaluate the potential benefits of adding docetaxel to S-1 without a platinum compound in patients with advanced gastric cancer. METHODS: Patients were randomly assigned to receive docetaxel plus S-1 or S-1 alone. The docetaxel plus S-1 group received docetaxel on day 1 and oral S-1 on days 1-14 of a 21-day cycle. The S-1 alone group received oral S-1 on days 1-28 of a 42-day cycle. The primary end point was overall survival. RESULTS: Of the 639 patients enrolled, 635 were eligible for analysis. The median overall survival was 12.5 months in the docetaxel plus S-1 group and 10.8 months in the S-1 alone group (p = 0.032). The median progression-free survival was 5.3 months in the docetaxel plus S-1 group and 4.2 months in the S-1 alone group (p = 0.001). As for adverse events, neutropenia was more frequent in the docetaxel plus S-1 group, but remained manageable. CONCLUSION: As first-line treatment for advanced gastric cancer, docetaxel plus S-1 significantly improves median overall and progression-free survival as compared with S-1 alone. (ClinicalTrials.gov number: NCT00287768).-
dc.description.statementOfResponsibilityopen-
dc.format.extent319~328-
dc.relation.isPartOfJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/drug therapy-
dc.subject.MESHAdenocarcinoma/mortality*-
dc.subject.MESHAdenocarcinoma/pathology-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHDrug Combinations-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHNeoplasm Recurrence, Local/drug therapy-
dc.subject.MESHNeoplasm Recurrence, Local/pathology-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHOxonic Acid/administration & dosage-
dc.subject.MESHPrognosis-
dc.subject.MESHProspective Studies-
dc.subject.MESHStomach Neoplasms/drug therapy-
dc.subject.MESHStomach Neoplasms/mortality*-
dc.subject.MESHStomach Neoplasms/pathology-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTaxoids/administration & dosage-
dc.subject.MESHTegafur/administration & dosage-
dc.subject.MESHYoung Adult-
dc.titleAddition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorWasaburo Koizumi-
dc.contributor.googleauthorYeul Hong Kim-
dc.contributor.googleauthorMasashi Fujii-
dc.contributor.googleauthorHoon Kyo Kim-
dc.contributor.googleauthorHiroshi Imamura-
dc.contributor.googleauthorKyung Hee Lee-
dc.contributor.googleauthorTakuo Hara-
dc.contributor.googleauthorHyun Cheol Chung-
dc.contributor.googleauthorTaroh Satoh-
dc.contributor.googleauthorJae Yong Cho-
dc.contributor.googleauthorHisashi Hosaka-
dc.contributor.googleauthorAkihito Tsuji-
dc.contributor.googleauthorAkinori Takagane-
dc.contributor.googleauthorMikito Inokuchi-
dc.contributor.googleauthorKazuaki Tanabe-
dc.contributor.googleauthorTatsuya Okuno-
dc.contributor.googleauthorMariko Ogura-
dc.contributor.googleauthorKazuhiro Yoshida-
dc.contributor.googleauthorMasahiro Takeuchi-
dc.contributor.googleauthorToshifusa Nakajima-
dc.identifier.doi10.1007/s00432-013-1563-5-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03773-
dc.contributor.localIdA03899-
dc.relation.journalcodeJ01283-
dc.identifier.eissn1432-1335-
dc.identifier.pmid24366758-
dc.subject.keywordAdvanced gastric cancer-
dc.subject.keywordChemotherapy-
dc.subject.keywordS-1-
dc.subject.keywordDocetaxel-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.citation.volume140-
dc.citation.number2-
dc.citation.startPage319-
dc.citation.endPage328-
dc.identifier.bibliographicCitationJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, Vol.140(2) : 319-328, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.